According to the Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) announcement, New Coronavirus (2019-nCoV) antigen detection kit (colloidal gold method), which was independently developed by the company’s subsidiary company, was awarded the People’s Republic of China medical device registration certificate (in vitro diagnostic reagent) issued by the State Administration of drug control in April 13, 2022. The product is used for the in vitro qualitative detection of New Coronavirus (2019-nCoV) Nucleocapsid (N) antigen in nasal swabs. It has been approved by the European Union CE and completed the registration of German BfArM, and has been included in the HSC Common List of the European Union health and Safety Committee (EU white list).
© China Stock Market News